CRDL
Cardiol Therapeutics Inc.
Price Chart
Latest Quote
$1.06
+0.00 (+0.00%)
Current Price
| Previous Close | $1.06 |
| Open | $1.06 |
| Day High | $1.08 |
| Day Low | $1.04 |
| Volume | 255,761 |
Stock Information
Note: Financial values converted from CAD to USD
| Shares Outstanding | 115.27M |
| Total Debt | $82K |
| Cash Equivalents | $19.55M |
| Net Income | $-25.69M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $122.19M |
| EPS (TTM) | $-0.28 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $94.63M |
| Income | $-25.69M |
| Book/sh | $0.16 |
| Cash/sh | $0.24 |
| Employees | 18 |
Financial Ratios
| Quick Ratio | 3.93 |
| Current Ratio | 4.39 |
| Debt/Eq | 0.48 |
Returns & Margins
| ROA | -78.25% |
| ROE | -173.96% |
Ownership
| Insider Ownership | 2.38% |
| Institutional Ownership | 24.92% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.29 |
| P/B | 6.68 |
Analyst Data
| Recommendation | none |
| Target Price | $7.14 |
Technical Indicators
| SMA20 | $1.15 |
| SMA50 | $1.29 |
| SMA200 | $1.11 |
| RSI | 25.00 |
| ATR | 0.0579 |
| Shares Float | 95.93M |
| Short Float | 1.71% |
| Short Ratio | 4.97 |
| Volatility | 0.48 |
| Rel Volume | 0.72 |
Performance History
| Week | -0.93% |
| Month | -15.87% |
| Quarter | +11.93% |
| 6 Months | +1.92% |
| YTD | +6.64% |
| Year | -22.63% |
| 3 Years | +41.52% |
| 5 Years | -59.86% |
| 10 Years | -71.67% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.06 | 258,500 |
| 2026-06-17 | $1.06 | 354,400 |
| 2026-06-16 | $1.06 | 369,200 |
| 2026-06-15 | $1.05 | 250,900 |
| 2026-06-12 | $1.03 | 288,400 |
| 2026-06-11 | $1.07 | 255,100 |
| 2026-06-10 | $1.05 | 376,000 |
| 2026-06-09 | $1.08 | 334,100 |
| 2026-06-08 | $1.08 | 344,700 |
| 2026-06-05 | $1.11 | 427,300 |
| 2026-06-04 | $1.15 | 474,500 |
| 2026-06-03 | $1.12 | 819,000 |
| 2026-06-02 | $1.15 | 414,800 |
| 2026-06-01 | $1.22 | 414,400 |
| 2026-05-29 | $1.22 | 335,400 |
| 2026-05-28 | $1.28 | 183,100 |
| 2026-05-27 | $1.28 | 334,800 |
| 2026-05-26 | $1.30 | 330,300 |
| 2026-05-22 | $1.32 | 281,300 |
| 2026-05-21 | $1.31 | 288,500 |
| 2026-05-20 | $1.30 | 259,500 |
| 2026-05-19 | $1.26 | 235,000 |
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
đ° Latest News
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Simply Wall St. âĸ 2026-05-15T16:22:54Z
Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.
MT Newswires âĸ 2026-04-28T12:07:56ZCardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise
MarketBeat âĸ 2026-04-15T10:15:39Z
Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial
MT Newswires âĸ 2026-04-01T18:24:19ZCardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference
MarketBeat âĸ 2026-03-08T23:02:26Z
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
Zacks âĸ 2026-03-03T13:07:00Z
Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long
Simply Wall St. âĸ 2026-01-12T15:38:16Z
TSX Penny Stocks To Watch In October 2025
Simply Wall St. âĸ 2025-10-21T19:05:13Z
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Zacks âĸ 2025-10-15T10:19:00Z
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Zacks âĸ 2025-10-14T14:57:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $24,471,436 | $28,721,849 | $21,240,464 | $29,477,199 |
| Other Income Expense | $-163,288 | $1,715,760 | $-271,877 | $6,537,544 |
| Net Non Operating Interest Income Expense | $518,007 | $850,989 | $1,453,658 | $882,573 |
| Operating Expense | $24,471,436 | $28,721,849 | $21,240,464 | $29,477,199 |
| General And Administrative Expense | $14,401,948 | $18,463,528 | $11,096,924 | $15,955,072 |
| Other Non Operating Income Expenses | - | $20,126 | $106,781 | $117,267 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-24,116,717 | $-26,155,101 | $-20,058,683 | $-22,057,082 |
| Net Interest Income | $518,007 | $850,989 | $1,453,658 | $882,573 |
| Interest Income | $518,007 | $850,989 | $1,453,658 | $882,573 |
| Normalized Income | $-23,953,429 | $-27,850,734 | $-19,680,025 | $-28,477,360 |
| Net Income From Continuing And Discontinued Operation | $-24,116,717 | $-26,155,101 | $-20,058,683 | $-22,057,082 |
| Net Income Common Stockholders | $-24,116,717 | $-26,155,101 | $-20,058,683 | $-22,057,082 |
| Net Income | $-24,116,717 | $-26,155,101 | $-20,058,683 | $-22,057,082 |
| Net Income Including Noncontrolling Interests | $-24,116,717 | $-26,155,101 | $-20,058,683 | $-22,057,082 |
| Net Income Continuous Operations | $-24,116,717 | $-26,155,101 | $-20,058,683 | $-22,057,082 |
| Pretax Income | $-24,116,717 | $-26,155,101 | $-20,058,683 | $-22,057,082 |
| Interest Income Non Operating | $518,007 | $850,989 | $1,453,658 | $882,573 |
| Operating Income | $-24,471,436 | $-28,721,849 | $-21,240,464 | $-29,477,199 |
| Depreciation Amortization Depletion Income Statement | $72,726 | $266,073 | - | - |
| Depreciation And Amortization In Income Statement | $72,726 | $266,073 | - | - |
| Amortization Of Intangibles Income Statement | $0 | $150,009 | - | - |
| Depreciation Income Statement | $72,726 | $116,064 | - | - |
| Per Share | ||||
| Diluted EPS | $-0.28 | $-0.36 | $-0.31 | $-0.35 |
| Basic EPS | $-0.28 | $-0.36 | $-0.31 | $-0.35 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-24,235,422 | $-30,151,410 | $-20,684,701 | $-35,740,657 |
| Total Unusual Items | $-163,288 | $1,695,634 | $-378,658 | $6,420,278 |
| Total Unusual Items Excluding Goodwill | $-163,288 | $1,695,634 | $-378,658 | $6,420,278 |
| Reconciled Depreciation | $72,726 | $266,073 | $177,105 | $156,820 |
| EBITDA (Bullshit earnings) | $-24,398,710 | $-28,455,776 | $-21,063,359 | $-29,320,380 |
| EBIT | $-24,471,436 | $-28,721,849 | $-21,240,464 | $-29,477,199 |
| Diluted Average Shares | $62,033,328 | $51,035,978 | $45,969,539 | $44,573,900 |
| Basic Average Shares | $62,033,328 | $51,035,978 | $45,969,539 | $44,573,900 |
| Diluted NI Availto Com Stockholders | $-24,116,717 | $-26,155,101 | $-20,058,683 | $-22,057,082 |
| Gain On Sale Of Security | $-163,288 | $1,695,634 | $-378,658 | $6,420,278 |
| Amortization | $0 | $150,009 | - | - |
| Research And Development | $9,996,763 | $9,992,248 | $10,143,540 | $13,522,127 |
| Selling General And Administration | $14,401,948 | $18,463,528 | $11,096,924 | $15,955,072 |
| Other Gand A | $7,824,294 | $9,252,617 | $11,096,924 | $15,955,072 |
| Salaries And Wages | $6,577,654 | $9,210,912 | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $12,748,853 | $17,634,231 | $19,992,974 | $37,015,463 |
| Total Assets | $16,843,708 | $22,722,491 | $26,171,651 | $44,233,413 |
| Total Non Current Assets | $84,214 | $139,479 | $390,370 | $421,122 |
| Current Assets | $16,759,494 | $22,583,012 | $25,781,281 | $43,812,291 |
| Prepaid Assets | $1,325,651 | $518,084 | $671,356 | $1,061,052 |
| Receivables | $161,303 | $257,877 | $199,581 | $342,435 |
| Other Receivables | $121,563 | $186,305 | $97,787 | $192,736 |
| Accounts Receivable | $39,740 | $71,572 | $101,793 | $149,699 |
| Cash Cash Equivalents And Short Term Investments | $15,272,540 | $21,807,051 | $24,910,345 | $42,408,804 |
| Cash And Cash Equivalents | $15,272,540 | $21,807,051 | $24,910,345 | $42,408,804 |
| Goodwill And Other Intangible Assets | - | $0 | $150,009 | $210,227 |
| Other Intangible Assets | - | - | $150,009 | $210,227 |
| Debt | ||||
| Total Debt | $89,512 | $113,051 | $124,324 | $51,965 |
| Long Term Debt And Capital Lease Obligation | $62,166 | $89,512 | $113,051 | $15,991 |
| Current Debt And Capital Lease Obligation | $27,346 | $23,539 | $11,273 | $35,974 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,094,855 | $5,088,261 | $6,028,668 | $7,007,723 |
| Total Non Current Liabilities Net Minority Interest | $62,166 | $89,512 | $113,051 | $15,991 |
| Current Liabilities | $4,032,688 | $4,998,748 | $5,915,616 | $6,991,732 |
| Other Current Liabilities | $1,524,543 | - | $169,847 | $299,437 |
| Payables And Accrued Expenses | $2,480,799 | $4,975,209 | $5,734,497 | $6,656,320 |
| Equity | ||||
| Common Stock Equity | $12,748,853 | $17,634,231 | $20,142,984 | $37,225,691 |
| Total Equity Gross Minority Interest | $12,748,853 | $17,634,231 | $20,142,984 | $37,225,691 |
| Stockholders Equity | $12,748,853 | $17,634,231 | $20,142,984 | $37,225,691 |
| Retained Earnings | $-151,945,351 | $-127,828,634 | $-101,673,534 | $-81,614,851 |
| Other Equity Interest | - | - | $2,508,641 | $2,508,641 |
| Other | ||||
| Ordinary Shares Number | $71,494,691 | $58,909,640 | $46,603,634 | $45,669,638 |
| Share Issued | $71,494,691 | $58,909,640 | $46,603,634 | $45,669,638 |
| Tangible Book Value | $12,748,853 | $17,634,231 | $19,992,974 | $37,015,463 |
| Invested Capital | $12,748,853 | $17,634,231 | $20,142,984 | $37,225,691 |
| Working Capital | $12,726,806 | $17,584,264 | $19,865,665 | $36,820,559 |
| Capital Lease Obligations | $89,512 | $113,051 | $124,324 | $51,965 |
| Total Capitalization | $12,748,853 | $17,634,231 | $20,142,984 | $37,225,691 |
| Additional Paid In Capital | $20,740,386 | $17,576,240 | $13,396,780 | $11,115,190 |
| Capital Stock | $143,953,819 | $127,886,625 | $105,911,096 | $105,216,710 |
| Common Stock | $143,953,819 | $127,886,625 | $105,911,096 | $105,216,710 |
| Long Term Capital Lease Obligation | $62,166 | $89,512 | $113,051 | $15,991 |
| Current Capital Lease Obligation | $27,346 | $23,539 | $11,273 | $35,974 |
| Net PPE | $84,214 | $139,479 | $240,361 | $210,895 |
| Accumulated Depreciation | $-623,720 | $-550,994 | $-468,343 | $-351,456 |
| Gross PPE | $707,933 | $690,473 | $708,704 | $562,351 |
| Leases | $169,185 | $169,185 | $169,185 | $169,185 |
| Other Properties | $366,678 | $366,678 | $400,091 | $265,409 |
| Machinery Furniture Equipment | $172,071 | $154,611 | $139,429 | $127,757 |
| Properties | $0 | $0 | $0 | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-17,028,548 | $-17,886,441 | $-18,002,390 | $-19,464,489 |
| Operating Activities | ||||
| Operating Cash Flow | $-17,011,088 | $-17,871,259 | $-17,956,529 | $-19,411,213 |
| Cash Flow From Continuing Operating Activities | $-17,011,088 | $-17,871,259 | $-17,956,529 | $-19,411,213 |
| Operating Gains Losses | $-91,066 | $-1,517,683 | $-673,011 | $-5,566,021 |
| Investing Activities | ||||
| Capital Expenditure | $-17,460 | $-15,182 | $-45,862 | $-53,276 |
| Investing Cash Flow | $-17,460 | $-15,182 | $-45,862 | $-53,276 |
| Cash Flow From Continuing Investing Activities | $-17,460 | $-15,182 | $-45,862 | $-53,276 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $11,436,906 | $15,228,972 | $0 | $0 |
| Financing Cash Flow | $11,081,673 | $13,435,311 | $-39,489 | $-38,461 |
| Cash Flow From Continuing Financing Activities | $11,081,673 | $13,435,311 | $-39,489 | $-38,461 |
| Net Other Financing Charges | $-340,175 | $-1,890,629 | - | - |
| Net Common Stock Issuance | $11,436,906 | $15,228,972 | $0 | $0 |
| Common Stock Issuance | $11,436,906 | $15,228,972 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-39,489 | $-29,617 | $-39,489 | $-38,461 |
| End Cash Position | $15,272,540 | $21,807,051 | $24,910,345 | $42,408,804 |
| Beginning Cash Position | $21,807,051 | $24,910,345 | $42,408,804 | $59,829,613 |
| Effect Of Exchange Rate Changes | $-587,635 | $1,347,836 | $543,421 | $2,082,141 |
| Changes In Cash | $-5,946,876 | $-4,451,130 | $-18,041,880 | $-19,502,950 |
| Proceeds From Stock Option Exercised | $24,431 | $126,585 | $0 | $0 |
| Net Issuance Payments Of Debt | $-39,489 | $-29,617 | $-39,489 | $-38,461 |
| Net Long Term Debt Issuance | $-39,489 | $-29,617 | $-39,489 | $-38,461 |
| Long Term Debt Payments | $-39,489 | $-29,617 | $-39,489 | $-38,461 |
| Net PPE Purchase And Sale | $-17,460 | $-15,182 | $-45,862 | $-53,276 |
| Purchase Of PPE | $-17,460 | $-15,182 | $-45,862 | $-53,276 |
| Change In Working Capital | $-522,953 | $-664,312 | $-389,273 | $4,098,991 |
| Change In Payables And Accrued Expense | $188,040 | $-759,288 | $-921,823 | $3,191,047 |
| Change In Prepaid Assets | $-807,568 | $153,272 | $389,696 | $960,051 |
| Change In Receivables | $96,574 | $-58,296 | $142,855 | $-52,107 |
| Changes In Account Receivables | $31,833 | $30,221 | $47,906 | $-102,820 |
| Other Non Cash Items | $15,950 | $18,344 | $23,087 | $381,107 |
| Stock Based Compensation | $7,630,972 | $10,181,420 | $2,964,246 | $3,574,973 |
| Depreciation Amortization Depletion | $72,726 | $266,073 | $177,105 | $156,820 |
| Depreciation And Amortization | $72,726 | $266,073 | $177,105 | $156,820 |
| Amortization Cash Flow | $0 | $150,009 | $60,218 | $60,218 |
| Amortization Of Intangibles | $0 | $150,009 | $60,218 | $60,218 |
| Depreciation | $72,726 | $116,064 | $116,887 | $96,601 |
| Gain Loss On Investment Securities | $-678,701 | $-169,847 | $-129,591 | $-3,483,881 |
| Net Foreign Currency Exchange Gain Loss | $587,635 | $-1,347,836 | $-543,421 | $-2,082,141 |
| Net Income From Continuing Operations | $-24,116,717 | $-26,155,101 | $-20,058,683 | $-22,057,082 |
| Change In Inventory | - | - | $0 | $0 |
Fetched: 2026-06-17